Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation

Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA. emmd@mail.med.upenn.edu

OBJECTIVES: We sought to determine whether the beneficial effects of amlodipine in heart failure may be mediated by a reduction in tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) levels. We postulated that TNF-alpha and IL-6 levels may also have predictive value in patients with congestive heart failure (CHF). BACKGROUND: The molecular mechanism for progression of CHF may involve cytokine overexpression. The effect of amlodipine on cytokine levels in patients with CHF is unknown. METHODS: In the Prospective Randomized Amlodipine Survival Evaluation (PRAISE) trial, we used enzyme-linked immunosorbent assay to measure plasma levels of TNF-alpha in 92 patients and IL-6 in 62 patients in New York Heart Association functional classes III and IV randomized to receive amlodipine (10 mg/day) or placebo. Blood samples were obtained for cytokine measurement at baseline and at 8 and 26 weeks after enrollment. RESULTS: The baseline amlodipine and placebo groups did not differ in demographics and cytokine levels. Mean (+/- SD) plasma levels of TNF-alpha were 5.69 +/- 0.32 pg/ml, and those of IL-6 were 9.23 +/- 1.26 pg/ml at baseline. These levels were elevated 6 and 10 times, respectively, compared with those of normal subjects (p < 0.001). Levels of TNF-alpha did not change significantly over the 26-week period (p = 0.69). However, IL-6 levels were significantly lower at 26 weeks in patients treated with amlodipine versus placebo (p = 0.007 by the Wilcoxon signed-rank test). An adverse event-CHF or death-occurred more commonly in patients with higher IL-6 levels. CONCLUSIONS: Amlodipine lowers plasma IL-6 levels in patients with CHF. The beneficial effect of amlodipine in CHF may be due to a reduction of cytokines such as IL-6.

This article has been cited by other articles:

				B. J. Wrigley, G. Y. H. Lip, and E. Shantsila The role of monocytes and inflammation in the pathophysiology of heart failure Eur J Heart Fail, November 1, 2011; 13(11): 1161 - 1171. [Abstract] [Full Text] [PDF]

				C. Avgeropoulou, I. Andreadou, S. Markantonis-Kyroudis, M. Demopoulou, P. Missovoulos, A. Androulakis, and I. Kallikazaros The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine Eur J Heart Fail, August 1, 2005; 7(5): 882 - 887. [Abstract] [Full Text] [PDF]

				S. Yang, R. Zheng, S. Hu, Y. Ma, M. A. Choudhry, J. L. Messina, L. W. Rue III, K. I. Bland, and I. H. Chaudry Mechanism of cardiac depression after trauma-hemorrhage: increased cardiomyocyte IL-6 and effect of sex steroids on IL-6 regulation and cardiac function Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2183 - H2191. [Abstract] [Full Text] [PDF]

				W.-H. Yin, J.-W. Chen, H.-L. Jen, M.-C. Chiang, W.-P. Huang, A.-N. Feng, S.-J. Lin, and M. S. Young The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure Eur J Heart Fail, August 1, 2003; 5(4): 507 - 516. [Abstract] [Full Text] [PDF]

				N. Mabuchi, T. Tsutamoto, A. Wada, M. Ohnishi, K. Maeda, M. Hayashi, and M. Kinoshita Relationship Between Interleukin-6 Production in the Lungs and Pulmonary Vascular Resistance in Patients With Congestive Heart Failure* Chest, April 1, 2002; 121(4): 1195 - 1202. [Abstract] [Full Text] [PDF]

				S. Adamopoulos, J. Parissis, D. Karatzas, C. Kroupis, M. Georgiadis, G. Karavolias, J. Paraskevaidis, K. Koniavitou, A. J. S. Coats, and D. T. Kremastinos Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fasligand system in patients with chronic heart failure J. Am. Coll. Cardiol., February 20, 2002; 39(4): 653 - 663. [Abstract] [Full Text] [PDF]

				T. Ohtsuka, M. Hamada, G. Hiasa, O. Sasaki, M. Suzuki, Y. Hara, Y. Shigematsu, and K. Hiwada Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy J. Am. Coll. Cardiol., February 1, 2001; 37(2): 412 - 417. [Abstract] [Full Text] [PDF]

				M. Rauchhaus, W. Doehner, D. P. Francis, C. Davos, M. Kemp, C. Liebenthal, J. Niebauer, J. Hooper, H.-D. Volk, A. J. S. Coats, et al. Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure Circulation, December 19, 2000; 102(25): 3060 - 3067. [Abstract] [Full Text] [PDF]

				D. M. Kaye, B. A. Ahlers, D. J. Autelitano, and J. P. F. Chin-Dusting In Vivo and In Vitro Evidence for Impaired Arginine Transport in Human Heart Failure Circulation, November 28, 2000; 102(22): 2707 - 2712. [Abstract] [Full Text] [PDF]

				K. Maeda, T. Tsutamoto, A. Wada, N. Mabuchi, M. Hayashi, T. Tsutsui, M. Ohnishi, M. Sawaki, M. Fujii, T. Matsumoto, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1587 - 1593. [Abstract] [Full Text] [PDF]

				B. Bozkurt Activation of cytokines as a mechanism of disease progression in heart failure Ann Rheum Dis, November 1, 2000; 59(90001): i90 - 93. [Full Text] [PDF]

				G. D. Pearson, J.-C. Veille, S. Rahimtoola, J. Hsia, C. M. Oakley, J. D. Hosenpud, A. Ansari, and K. L. Baughman Peripartum Cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) Workshop Recommendations and Review JAMA, March 1, 2000; 283(9): 1183 - 1188. [Abstract] [Full Text] [PDF]

				F. A. Recchia, R. D. Bernstein, P. B. Sehgal, N. R. Ferreri, and T. H. Hintze Cytokines Are Not a Requisite Part of the Pathophysiology Leading to Cardiac Decompensation Exp Biol Med, January 1, 2000; 223(1): 47 - 52. [Abstract] [Full Text] [PDF]

				L. Gullestad, P.a. Aukrust, T. Ueland, T. Espevik, G. Yee, R. Vagelos, S. S. Froland, and M. Fowler Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure J. Am. Coll. Cardiol., December 1, 1999; 34(7): 2061 - 2067. [Abstract] [Full Text] [PDF]

				Z. Dibbs, J. Thornby, B. G. White, and D. L. Mann Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials J. Am. Coll. Cardiol., June 1, 1999; 33(7): 1935 - 1942. [Abstract] [Full Text] [PDF]

				D. R. Wagner, T. Kubota, V. J. Sanders, C. F. McTiernan, and A. M. Feldman Differential regulation of cardiac expression of IL-6 and TNF-alpha by A2- and A3-adenosine receptors Am J Physiol Heart Circ Physiol, June 1, 1999; 276(6): H2141 - H2147. [Abstract] [Full Text] [PDF]

				S. Sasayama, A. Matsumori, and Y. Kihara New insights into the pathophysiological role for cytokines in heart failure Cardiovasc Res, June 1, 1999; 42(3): 557 - 564. [Full Text] [PDF]